Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer.

Cancer Manag Res · 2019 · PMC6514123 · PMID 31190993

Europe PMC DOI

hedged sentence

0.0130

closest p · 0.3× alpha

0.0130

boldest claim

The sentences

highly significantP =0.013actually significant

The pooled OR estimate showed a highly significant reduction in the risk of POF (OR 0.43; 95% CI: 0.22–0.84; P =0.013) in patients receiving GnRH agonists.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.